Tempest Therapeutics (TPST) EBT Margin (2015 - 2018)
Tempest Therapeutics (TPST) posted EBT Margin of 10325.45% for Q3 2018, down 8.58% sequentially from 9509.88% in Q2 2018, and up 638169.0% YoY from N/an in Q3 2017.
Tempest Therapeutics (TPST) EBT Margin (2015 - 2018) Analysis & Trends
Tempest Therapeutics has reported EBT Margin for 4 years, with the latest figure at 10325.45% in Q3 2018.
- Quarterly EBT Margin rose 638169.0% year-over-year to 10325.45% in Q3 2018, while the trailing twelve-month figure through Sep 2018 was 9947.62% (up 1013695.0% YoY) and the FY2017 annual result came in at 17256.95%, down 469049.0% from the prior year.
- EBT Margin eased to 10325.45% in Q3 2018 per TPST's latest filing, from 9509.88% in the prior quarter.
- Over five years, EBT Margin peaked at 9334.07% in Q4 2017 and troughed at 114706.67% in Q1 2015.
- A 4-year average of 24349.17% and a median of 14851.37% in 2016 frame the typical range for EBT Margin.
- The sharpest annual moves came in 2016 and 2017: EBT Margin soared 9985530 bps in 2016, then sank 1183664 bps in 2017.
- Over 4 years, EBT Margin stood at 13073.89% in 2015, then slumped by 43 bps to 18726.45% in 2016, then jumped by 50 bps to 9334.07% in 2017, then retreated by 11 bps to 10325.45% in 2018.
- According to Business Quant data, EBT Margin over the past three periods registered 10325.45%, 9509.88%, and 11000.0% for Q3 2018, Q2 2018, and Q1 2018 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 41.75% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 35.61% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 35.71% |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -528.97% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 18.33% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 13.77% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -25.06% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -2.67% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 12.09% |
| 10 | Tempest Therapeutics | 4.32 Mn | 3.52 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2018 | -10,325.45% |
| Jun 30, 2018 | -9,509.88% |
| Mar 31, 2018 | -11,000.00% |
| Dec 31, 2017 | -9,334.07% |
| Sep 30, 2017 | -16,707.14% |
| Jun 30, 2017 | -21,634.52% |
| Mar 31, 2017 | -23,628.57% |
| Dec 31, 2016 | -18,726.45% |
| Sep 30, 2016 | -9,745.69% |
| Jun 30, 2016 | -9,797.88% |
| Mar 31, 2016 | -14,851.37% |
| Dec 31, 2015 | -13,073.89% |
| Sep 30, 2015 | -23,896.00% |
| Jun 30, 2015 | -58,300.00% |
| Mar 31, 2015 | -114,706.67% |